# NM_001077706.3(ECT2L):c.859C>T (p.Arg287Trp)

https://sugi.bio/variant/ect2l-p-arg287trp

## Summary

**ECT2L p.Arg287Trp (c.859C>T)** is classified **Uncertain significance** in ECT2L (ClinVar, Single submitter, 1 submitter; last evaluated 2021-10-06). AlphaMissense: likely benign (0.0923); Ultra-rare (popmax 0.0165%, mid).

**At a glance:** Uncertain significance · review: Single submitter · rsID rs200093583 · 1 submitter · AlphaMissense likely benign · ultra-rare (popmax 0.0165%, mid)

## For patients & families {#patients}

This is a change in the ECT2L gene that is currently of uncertain significance — a definitive interpretation has not yet been established, submitted by 1 submitter.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [ECT2L](https://sugi.bio/atlas/gene/ECT2L/) |
| Protein change (HGVS p.) | p.Arg287Trp |
| Coding change (HGVS c.) | c.859C>T |
| MANE Select transcript | [NM_001077706](https://www.ncbi.nlm.nih.gov/nuccore/NM_001077706) |
| dbSNP | [rs200093583](https://www.ncbi.nlm.nih.gov/snp/rs200093583/) |
| Variant type | single nucleotide variant |
| Location | chr6:138846633-138846633 (GRCh38) |
| ClinVar | [VCV3087110](https://www.ncbi.nlm.nih.gov/clinvar/variation/3087110/) |

**All HGVS expressions:** `NC_000006.11:g.139167770C>T`, `NC_000006.12:g.138846633C>T`, `NM_001077706.3:c.859C>T`, `NM_001195037.2:c.859C>T`

## Computational & population evidence {#evidence}

**Concordance:** ClinVar classifies this **uncertain**; the computational predictors unanimously lean **tolerated** — a triage signal, not a reclassification.

- AlphaMissense **likely benign** (0.0923)
- REVEL 0.154 (moderately benign-leaning) — agrees with AlphaMissense
- SaProt LLR -8.632 (tolerated) — agrees with AlphaMissense
- → **In-silico consensus:** AlphaMissense, REVEL and SaProt all call this tolerated
- SpliceAI predicts **donor loss** (Δ 0.43) — a splice-altering prediction on an uncertain variant — a signal for review
- Conservation: phyloP 1.037, GERP 0.605 — weakly conserved position
- CADD: **PHRED 19.42**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 0.95** across the covering region of the MANE Select transcript (138,813,275–138,902,624), spanning 89,349 bp. Chi-square p 0.11. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI deltas (raw): acceptor loss **0.00**, donor loss **0.43**, acceptor gain **0.00**, donor gain **0.00**. Largest is donor loss.
- SpliceAI deltas (masked): acceptor loss **0.00**, donor loss **0.43**, acceptor gain **0.00**, donor gain **0.00**.
- Pangolin: Δ**0.26** (loss), gain 0.00 / loss 0.26. Agrees with SpliceAI. An independent predictor to SpliceAI — a different model trained on different data. *Descriptive; ClinGen's SVI calibration covers SpliceAI, not Pangolin, so no ACMG code is assigned.*
- Population frequency (gnomAD v4.1): grpmax **0.0165%** (mid) · FAF95 0.00758% · FAF99 0.00707% · 1/6,074 in the highest group · 162/1,610,386 alleles overall — ultra-rare (popmax 0.0165%, mid).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Ashkenazi Jewish (not grpmax-eligible) | 0.115% | 866 |
| Middle Eastern (grpmax) | 0.0165% | 6,074 |
| South Asian | 0.0122% | 8,211 |
| Remaining individuals (not grpmax-eligible) | 0.00963% | 10,386 |
| European (non-Finnish) | 0.009% | 11,117 |
| Admixed American | 0.00336% | 29,758 |
| African / African-American | 0.00268% | 37,344 |

Ashkenazi Jewish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**ECT2L** population constraint: LOEUF 1.127, pLI 6.6862e-35, missense-Z 0.99586. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 74.75, 22% of residues very-high.

**1 experimental structure(s)** (PDB): [11XU](https://www.rcsb.org/structure/11XU).

## Clinical significance {#significance}

**Uncertain significance** — review status Single submitter *(criteria provided, single submitter)*, last evaluated 2021-10-06.

**Submitter consensus:** unanimous (1/1 Uncertain significance).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Ambry Genetics | Uncertain significance | criteria provided, single submitter | clinical testing | 2021-10-06 |

**Reported phenotype names (ClinVar):** not specified, AllHighlyPenetrant.

## Similar variants {#similar}

Related ECT2L variant pages (same residue, condition, or type): [ECT2L p.Ala147Thr](/variant/ect2l-p-ala147thr), [ECT2L p.Ala161Thr](/variant/ect2l-p-ala161thr), [ECT2L p.Ala299Val](/variant/ect2l-p-ala299val), [ECT2L p.Ala401Ser](/variant/ect2l-p-ala401ser), [ECT2L p.Ala443Ser](/variant/ect2l-p-ala443ser), [ECT2L p.Ala515Gly](/variant/ect2l-p-ala515gly), [ECT2L p.Ala599Thr](/variant/ect2l-p-ala599thr), [ECT2L p.Ala605Gly](/variant/ect2l-p-ala605gly).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-14); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 3087110). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*